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Abstract
Background: The ability to properly model intravascular steps in metastasis is essential in identifying key physical, cellular,
and molecular determinants that can be targeted therapeutically to prevent metastatic disease. Research on the vascular
microenvironment has been hindered by challenges in studying this compartment in metastasis under conditions that
reproduce in vivo physiology while allowing facile experimental manipulation.
Methodology/Principal Findings: We present a microfluidic vasculature system to model interactions between circulating
breast cancer cells with microvascular endothelium at potential sites of metastasis. The microfluidic vasculature produces
spatially-restricted stimulation from the basal side of the endothelium that models both organ-specific localization and
polarization of chemokines and many other signaling molecules under variable flow conditions. We used this microfluidic
system to produce site-specific stimulation of microvascular endothelium with CXCL12, a chemokine strongly implicated in
metastasis.
Conclusions/Significance: When added from the basal side, CXCL12 acts through receptor CXCR4 on endothelium to
promote adhesion of circulating breast cancer cells, independent of CXCL12 receptors CXCR4 or CXCR7 on tumor cells.
These studies suggest that targeting CXCL12-CXCR4 signaling in endothelium may limit metastases in breast and other
cancers and highlight the unique capabilities of our microfluidic device to advance studies of the intravascular
microenvironment in metastasis.
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Introduction
Trafficking of cells through the vasculature and arrest of
circulating cells on endothelium at specific sites are critical steps in
a wide variety of physiologic and disease processes, including
immune surveillance [1–3], inflammation [4–6], and metastatic
cancer [7–9]. In particular, specific interactions between circulat-
ing cancer cells and vascular endothelium are proposed to control
patterns of metastasis for breast [10], lung [11], and other
common solid cancers [12]. However, mechanisms for organ-
specific tropism of metastatic cancer cells remain poorly defined.
Identifying molecular determinants of trafficking and arrest of
circulating cancer cells on endothelium at characteristic sites of
metastatic disease has been limited in large part by challenges of
studying the intravascular microenvironment under physiologic
conditions. In vitro assays of cancer cells and endothelium typically
are performed under static, biochemically homogeneousconditions.
These static assays do not accurately model intravascular events in
metastasis because blood flow alters gene expression [13,14],
mechanical properties of cells [15,16], and cell adhesion [17,18].
Furthermore, all cells in a culture well are exposed to the same
biochemicalmilieu,unlike physiologicconditionswheregradients of
signaling molecules in different anatomic locations typically are
presented to the basal surface of endothelial cells [19,20]. By
comparison, animal models reproduce key physiologic features of
metastatic cancer in humans, but it is difficult to selectively
manipulateandcontrol experimental conditionsinthe intravascular
microenvironment in vivo. Animal models of metastasis also are
time-consuming, labor-intensive, and expensive.
We have engineered a new microfluidic model of the
vasculature to overcome limitations of existing systems and
advance studies of the intravascular compartment in cancer
metastasis and other diseases. This microfluidic device produces
defined flow rates within a range of physiologic levels and enables
real-time bright field and fluorescence imaging of circulating
cancer cells and microvascular endothelium. The device also
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5756allows region-specific treatment of endothelium from the basal
side, recreating organ-specific localization of signaling molecules
produced by stromal cells in the extravascular space. This also
mimics serial interaction of circulating tumor cells with endothelia
of differing potentials to promote cell adhesion and formation of
metastases. To establish the utility of this microfluidic device for
studying intravascular steps in metastasis, we investigated effects of
chemokine CXCL12 on adhesion of circulating breast cancer cells
to endothelium. High levels of CXCL12 are expressed by
parenchymal cells in organs commonly affected by metastatic
breast cancer, such as liver, bone, and brain [21], suggesting that
gradients of CXCL12 regulate homing of disseminated breast
cancer cells to endothelium in these sites. CXCL12-mediated
tropism of malignant breast [21], lung [11], and other cancer cells
for characteristic sites of metastatic disease has been attributed
predominantly to signaling through receptor CXCR4 on tumor
cells [22]. However, pro-metastatic effects of CXCL12 also may
be regulated through CXCR4 on vascular endothelium [23],
which upregulates and activates adhesion molecules to promote
stable interactions with circulating cells [24], and/or CXCR7
[25], a newly identified second receptor for CXCL12 [26].
Using the microfluidic vasculature to selectively manipulate
cancer cells and endothelium, we demonstrate that circulating
breast cancer cells preferentially adhere to endothelium stimulated
from the basal side with CXCL12. CXCL12 functions through
CXCR4 on endothelial cells to significantly enhance adhesion of
circulating breast cancer cells, independent of CXCR4 or CXCR7
on cancer cells. These results provide new insights into pro-
metastatic effects of CXCL12 in the intravascular microenviron-
ment, focusing attention on CXCL12-CXCR4 in vascular
endothelium as a potential therapeutic target to block metastasis.
Moreover, the research establishes this microfluidic vasculature
technology as a versatile, physiologic model for future studies of
the intravascular microenvironment in metastasis and other
disease processes.
Results
Fabrication of the microfluidic device
The microfluidic vasculature is comprised of two poly(dimethy-
siloxane) (PDMS) layers sandwiching a thin, porous, and optically
clear polyester membrane (Figure 1A, B). The top PDMS layer
features a channel with a funnel–shaped inlet that intersects
regionally distinct, perpendicularly-oriented channels in the
bottom PDMS layer (Figure 1D, E). The top channel (60 mm
height, 800 mm width) contains a confluent monolayer of human
dermal microvascular endothelial cells (HDMECs) (Figure 1C)
cultured on the polyester membrane with 400 nm pores to permit
diffusion of biomolecules between the top and bottom channels
(Figure 1B) as used in traditional Transwell inserts for cell culture.
The regions of the top channel that intersect one of the bottom
channels (60 mm height) are designated as either the upstream or
downstream region (Figure 1C, F), depending on the location
relative to the funnel-shaped inlet. By activating endothelia over
only one of the regions, the device reproduces serial interactions of
tumor cells with endothelia of differing metastasis-supporting
potential as occur physiologically.
This setup enables simultaneous and distinct localization of
chemokines on the basal face and flow on the apical face of the
endothelium (Figure 1B). This capability provides proper model-
ing of the directionality of chemokine stimulation (basal originat-
ing instead of apical) at the vasculature of target sites for
metastasis; a directionality previously shown to differentially
regulate endothelial function [27]. Comparisons with the specific
endothelial cells used in this study also showed that almost twice as
much CXCL12 binds to the endothelium when treated from
below or basally compared to apically (Figure 2A) (p,0.05). In
addition, approximately twice as many MDA-MB-231 (231-
control) breast cancer cells adhere onto the endothelium when
the endothelium is treated with CXCL12 basally compared to
apically. (Figure 2B) (p,0.05).
Region selective treatment of the microfluidic
endothelium
HDMECs in the upstream and downstream region can be
selectively treated with biomolecules from the lower channels,
allowing direct comparison of cancer cell adhesion onto stimulated
versus non-stimulated regions of the endothelium (Figure 1G). We
observed, for example, significantly greater adhesion of circulating
MDA-MB-231 (231-control) breast cancer cells onto the region of
the endothelium treated with the pro-inflammatory cytokine
tumor necrosis factor-a (TNF-a) compared to the untreated
region at shear stress levels of 0.50 dyn cm
22 (Figure 1G,
Supplemental Figure S1A) and 2.50 dyn cm
22 (Supplemental
Figure S1B) (p,0.02). Analysis of adhesion selectivity, defined as
the ratio of 231-control cells adhering to the TNF-a treated region
of the endothelium relative to the untreated region, provides
further useful insights. Here, we found that the adhesion selectivity
towards TNF-a treated endothelium was statistically greater at
2.50 dyn cm
22 compared to both 0 and 0.50 dyn cm
22 (Supple-
mental Figure S1C (p,0.05) while the total number of cells
adhered decreased (Supplemental Figure S1A, B).
Adhesion of cancer cells stably expressing CXCR4 or
CXCR7 onto microfluidic endothelium
Previous reports have shown that CXCR4 expression in cancer
cells promotes metastasis to distant organs such as the lung [21,28]
and that CXCR7 expression in cancer cells enhances adhesion
onto endothelium under static conditions [26]. We compared 231-
control cells to MDA-MB-231 cells stably expressing CXCR4
(231-CXCR4) or CXCR7 (231-CXCR7) (Figure 3A, B) to assess
effects of CXCL12 chemokine receptors on cancer cells in
mediating adhesion onto the microfluidic endothelium. For each
of the three cancer cell types, adhesion preference was towards
CXCL12-treated endothelium over the corresponding untreated
endothelium in the same device (Figure 3C) (p,0.05). For all three
cancer cell types, adhesion selectivity towards CXCL12-treated
endothelium increased with increasing flow rates among 0, 0.50,
and 2.50 dyn cm
22 (Figure 4) (p,0.05). The level of adhesion of
the three cancer cell types was statistically different on both the
CXCL12-treated and untreated endothelium (Figure 3C) (p,0.05)
with the adhesion of 231-CXCR4 and 231-CXCR7 cells being
significantly greater than 231-control cells (p,0.05). While
CXCR4 or CXCR7 expression on circulating breast cancer cells
increased adhesion to endothelium (Figure 3C), CXCL12-
dependent enhancements in adhesion or adhesion selectivity were,
surprisingly, statistically the same (Figure 3D) (p=0.48) and
therefore independent of expression of CXCR4 or CXCR7 on
cancer cells.
CXCR4 on endothelial cells mediates adhesion of cancer
cells
To evaluate this surprising lack of difference in adhesion
selectivity, we next turned our attention to how CXCL12 and
receptors CXCR4 and CXCR7 on the vascular endothelia, rather
than on cancer cells, may be key determinants in the intravascular
adhesion step of metastasis. CXCL12 signaling in endothelial cells
Metastasis on a Chip
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promoting stable interactions with circulating cells [24]. CXCL12
upregulated CXCR4 in HDMECs whereas TNF-a upregulated
both CXCR4 and CXCR7 (Figure 5A). HDMECs treated with
CXCL12 activated AKT, a known downstream effector of
CXCR4 [29], showing intact signaling in these cells (Figure 5B).
We region selectively treated this endothelium with various
combinations of CXCL12, TNF-a and AMD3100, a specific
inhibitor of CXCL12 binding to CXCR4 but not CXCR7 [30] To
eliminate confounding effects from cancer cell signaling we focused
on 231-control breast cancer cells, which do not express CXCR4 or
CXCR7, bind bioluminescent chemokine, or signal in response to
Figure 1. Microfluidic vasculature enables region-specific activation of endothelium under physiological flow conditions. (A)
Schematic of the poly(dimethysiloxane) (PDMS) microfluidic device demonstrating multi-layer fabrication with a thin, porous polyester membrane
sandwiched by the top and bottom PDMS layers. (B) Chemokine in the bottom channel activates the endothelium from the basal face while cancer
cells flow in the top channel above the endothelium. (C) Phase contrast image of HDMECs cultured in the microfluidic device. The image depicts the
entire length of the endothelium with the upstream, middle, and downstream regions clearly demarcated from each other. Scale bar represents
800 mm. (D) Photograph of the microfluidic device loaded with blue dye in the top channel and red dye in the two bottom channels. (E) Top view of
the microfluidic device. Fluid flows away from the funnel-shaped inlet and through the top channel. (F) Validation of region-specific stimulation of
endothelium. The upstream and downstream lower channels were filled with Syto 64, a fluorescent dye that stains cells. HDMECs overlying the
upstream and downstream bottom channels, but not HDMECs in the middle of the channel fluoresce. Fluorescence was evident within 15 minutes,
remained spatially-restricted for at least 5.5 hours, and persisted after 30 minutes of flow through the top channel. Image shows the 5.5 hour point
after initial treatment. Scale bar represents 800 mm. (G) Representative fluorescent images of adhesion of 231-control cells (stably expressing GFP)
onto region-specific TNF-a treated endothelium under 0.50 dyn cm
22 shear stress flow conditions. In these images, the downstream region was
treated with TNF-a for 5 h (denoted by a ‘+’) while the upstream and middle regions were left untreated. Scale bar represents 200 mm.
doi:10.1371/journal.pone.0005756.g001
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preferential adhesion to the treated endothelium for all four of the
treatment combinations except for CXCL12+AMD3100 under both
0.50 and 2.50 dyn cm
22 flow conditions (Figure 6A, B). AMD3100
was able to return adhesion to baseline values at both flow rates,
showing that the enhanced adhesion selectivity of circulating cancer
cells is due to CXCL12 signaling through CXCR4 on the vascular
endothelium (Figure 6A, B). Effects of CXCL12 are additive with
enhanced adhesion mediated by treatment with TNF-a,a n dt h e
CXCL12-dependent component can be inhibited with a specific
chemical probe AMD3100. When 231-control cells were pre-treated
with either AMD3100 or a neutralizing antibody to CXCR7 (11G8),
the level of adhesion was comparable to no pre-treatment of 231-
control cells onto both CXCL12 treated and untreated regions of the
endothelium (p.0.34) (Figure 6C). Furthermore, the 231-control
cells maintained adhesion preference to CXCL12 treated endothe-
lium when pre-treated with AMD3100 or anti-CXCR7 antibody
(p,0.05). Because inhibiting CXCR4 or CXCR7 only on 231-
control cancer cells did not affect adhesion, these data further
emphasize that basal treatment with CXCL12 acts through
endothelial CXCR4 to significantly enhance adhesion of circulating
cancer cells.
Discussion
We have described a compact, easily-fabricated microfluidic
system to model serial interactions of circulating cancer cells with a
vascular endothelium at defined sites stimulated extravascularly
from the basal side by chemokines. The microfluidic vasculature
reproduces preferential adhesion of circulating cancer cells to
endothelia in organs and tissues with high levels of CXCL12 in vivo
[31]. This system is a substantial advancement over previously
described in vitro flow-based assay systems in that it possesses a
unique blend of: (i) prolonged, extravascular stimulation of vascular
endothelium with CXCL12, modeling both the high levels and
directionality of this chemokine in target organs for metastatic
breast and other cancers [21] and (ii) region-specific endothelium
stimulation with chemokines to enable comparison of cancer cell
adhesion to endothelium of differing metastatic potential within the
same experiment. Furthermore, in comparison to static assay
systems, our system delivers physiologically-relevant flow conditions
in micron-scale channels that reveal enhanced adhesion selectivity
not observed under static conditions (Supplementary Figures S1C,
Figure 4). This combination of capabilities is novel for an in vitro
system and enables our system to evaluate the factors that mediate
intravascular adhesion of circulating cancer cells in the context of
physiologically defined chemical environments and physical forces.
Given its attributes, our system would also be useful for studies
involving immune cell trafficking to endothelium either in
response to chemokines such as CXCL12 [32] or inflammatory
cytokines such as TNF-a [33]. Moreover, by integrating the
principles of Transwell inserts into our microfluidic device, our
system can address key differences seen in activation of
endothelium from apical versus basal side stimulation but in the
context of flow. For instance, it has been shown that TNF-a elicits
greater leukocyte transendothelial migration across endothelium
treated from the basal versus apical side [34] which suggests that
spatial localization of adhesion molecules may be influenced by
directionality of cytokine stimulation. We demonstrated similar
results with CXCL12 by showing twice as much binding of
CXCL12 and adhesion of 231-control cells onto endothelium
stimulated from the basal side compared to apical (Figure 2). Since
TNF-a is produced mostly by macrophages located basal or
extravascular to the endothelium [35,36], our system properly
Figure 2. Enhanced binding of CXCL12 presented to the basal
versus apical surface of endothelium mediates increased
adhesion of cancer cells. (A) HDMEC cells 2 cultured on transwell
inserts were incubated with < 40 ng ml
21 CXCL12-GL added to either
the top (apical) or bottom (basal) compartment for 5 hours. Control
wells were incubated with equal amount of unfused GL (based on
ioluminescence) added to either the top or bottom compartment. Cell-
associated luciferase activity from CXCL12-GL or GL was quantified by
bioluminescence imaging. Data are mean values combined from two
independent experiments (n=4, 5 for each condition). Inset shows
representative bioluminescence images of CXCL12-GL associated with
endothelial cells. Images are presented as a pseudocolor display with
red and blue depicting the highest and lowest levels of photons,
respectively. Note, 40 ng ml
21 is the highest concentration of CXCL12-
GL that we can collect. (b) HDMECs in transwells were treated with
100 ng ml
21 CXCL12 either apically or basally. Following incubation
with 231-control cancer cells and subsequent washing to remove non-
adherent cells, approximately twice as many cancer cells remain
adhered onto endothelium treated with CXCL12 basally versus apically.
The fraction of cells that remain adhered was calculated from the
number of cancer cells added into empty wells from the same cell
suspension. n=36 for each condition. *, p,0.05.
doi:10.1371/journal.pone.0005756.g002
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attribute compared to other in vitro flow-based systems. Our design
also enables simultaneous basal chemokine and apical fluid
mechanical stimulation of endothelia in a reagent efficient
manner. Microliter amounts of expensive chemokine solution
are localized to the bottom compartment while flow substantive
enough to deliver shear stress levels known to alter gene expression
[13,14] can occur on the apical side of the endothelium allowing
for studies that otherwise may be cost prohibitive in macroscopic
or even other microfluidic systems. Furthermore, we envision our
system to be a highly versatile and modular platform that can
readily acquire additional physiologically important components
to help provide further insights into metastasis biology. For
instance, our system can be a useful co-culture model of
endothelial cells with relevant supporting cells from target sites
of metastasis cultured in the bottom channel. This approach is
similar to what is seen in previously described macroscopic flow-
based systems that integrate Transwell inserts [37,38] but our
system would retain the region-specific stimulation of the
endothelium that is unique to our microfluidic system.
Using our microfluidic endothelium, we confirmed that
CXCR4 or CXCR7 on breast cancer cells promotes intravascular
adhesion throughout the channel (Figure 3C), supporting a
mechanism through which these receptors expressed on cancer
cells promote metastasis [26,28]. These effects of CXCR4 and
CXCR7 on circulating cancer cells were observed in the absence
of chemokine ligand, suggesting that basal, ligand-independent
activation of these seven-transmembrane receptors is sufficient to
increase adhesion to endothelium. CXCR4 is known to promote
cell adhesion by stimulating binding of integrins, such as a4b1 and
Figure 3. Endothelial cells mediate CXCL12-dependent enhancement in adhesion of cancer cells. (A) Flow cytometry with antibodies to
CXCR4 (12G5) or CXCR7 (11G8) shows expression in stably transduced cell lines and absence of these receptors in 231-control cells. Filled histogram,
isotype antibody control; open histogram, antibody stain. Isotype control staining overlapped with unstained cells (not shown on the plots). (B)
CXCL12-dependent activation of AKT in 231 cells determined by Western Blot. Breast cancer cell lines were cultured overnight in medium containing
0.5% serum and then treated with 100 ng ml
21 CXCL12 for 3 min, 10 min, or no CXCL12 (NT). Cell lysates were probed for phosphorylation of AKT at
serine 473. Blots then were stripped and probed for total AKT as a loading control. Similar results were obtained with 300 ng ml
21 and incubations
extending through 30 minutes. (C) Adhesion of 231-CXCR4, 231-CXCR7, and 231-control cancer cells onto CXCL12 treated versus untreated
endothelium under 0.50 dyn cm
22 shear flow conditions. For all three cancer cell-types, adhesion selectivity was towards the CXCL12 treated region
of the endothelium over the corresponding untreated region (*). The level of adhesion of the three different cancer cell-types was statistically
different on both the CXCL12 treated and untreated endothelial regions (**). Data are expressed as mean+s.e.m. (D) Adhesion selectivity of cancer
cells towards the CXCL12 treated endothelial region over the untreated region under 0.50 dyn cm
22 flow conditions. Adhesion selectivity to CXCL12-
stimulated endothelium was comparable for all cancer cell lines, regardless of expression of CXCR4 or CXCR7. #, p=0.48. Statistical significance as
determined by Mann-Whitney (*, p,0.05) for pair wise comparison and Kruskal-Wallis (**, p,0.05) for comparison of more than two groups.
doi:10.1371/journal.pone.0005756.g003
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shown to promote adhesion of non-transformed and cancer cells,
although mechanisms of action remain to be fully defined [25,26].
We determined that pro-metastatic effects of CXCL12 on
circulating cancer cells are mediated at least in part through
vascular endothelium. Stimulation of HDMECs with CXCL12
enhanced adhesion selectivity of circulating breast cancer cells by a
comparable amount, regardless of expression of chemokine
receptors CXCR4 or CXCR7 on cancer cells (Figure 3D). These
results indicate that responses of vascular endothelium to the
surrounding molecular environment contribute substantially to
intravascular adhesion of cancer cells, a phenomenon difficult to
address with in vivo studies. Furthermore, inhibiting CXCL12-
CXCR4 signaling on endothelium significantly reduced adhesion of
circulating breast cancer cells (Figure 6A, B) suggesting that
inhibiting chemokine receptors on endothelial cells may be of equal
or greater importance for preventing initial steps of intravascular
cancer cell adhesion as compared with targeting these receptors on
cancer cells. Endothelial cells are particularly appealing as
therapeutic targets to block metastasis because these cells do not
possess the same barriers to drug delivery as solid tumors [40], are
readily accessible to systemic delivery of anticancer agents, and are
less likely to mutate and acquire drug resistance, as compared with
geneticallyunstable cancercells.By combiningthe convenience and
cost-effectiveness of in vitro cell culture with key physical, cellular,
and molecular components of the in vivo vasculature, we expect that
the described microfluidic endothelium will accelerate studies of the
intravascular microenvironment in metastatic cancer and develop-
ment of new therapies to block this key step in metastasis.
Methods
Device fabrication
The microfluidic device (Figure 1A) consisted of two channel
layers of 12:1 base to curing agent poly(dimethylsiloxane) (PDMS,
Sylgard 184, Dow Corning) that sandwiched a semi-porous,
optically clear polyester membrane [41]. The layers were sealed
together using a very thin (,10 mm) and uniform PDMS/toluene
glue that provided robust, leakage-free sealing [42]. The top and
bottom PDMS layers were molded as previously described [41]
except the top layer featured a funnel-shaped inlet that was
molded to intersect the inlet of the top channel (Figure 1A). The
molded funnel-shaped inlet eliminated cell clogging that we
observed in conventional cylindrical shaped inlets formed with
hole punchers. This design feature enabled: a) more uniform
HDMEC seeding and resulting monolayer through the entire
length of the top channel and b) more consistent cancer cell
suspension during the flow-based intravascular adhesion experi-
ments (see below). The dimensions of each of the described regions
(upstream, middle, and downstream) are 4,400 mm (or 4.4 mm)
long by 800 mm wide. After the device was assembled, tubing was
attached to the outlet of the top channel and to the inlets of the
bottom channels using epoxy. Subsequently, the devices were
Figure 4. Adhesion selectivity of cancer cells onto the CXCL12
treated endothelial region over the untreated region at
different flow conditions. The boxplots were grouped together by
cancer cell type at 0 (or static), 0.50, and 2.50 dyn cm
22 flow conditions.
For each cell type, the adhesion selectivity was statistically different for
the different flow conditions (**, p,0.05) with the selectivity consistently
increasing from static to flow conditions. n=4–6 for each condition.
doi:10.1371/journal.pone.0005756.g004
Figure 5. Characterization of CXCL12-mediated response in
HDMECs. (A) Chemokine receptor expression in HDMECs determined
by reverse transcription PCR (RT-PCR). HDMECs show expression of
CXCR4 but not CXCR7 under basal conditions. CXCR4 on HDMECs is
upregulated compared to basal conditions by CXCL12 and TNF-a.
CXCR7 is upregulated by TNF-a only. RT-PCR for the housekeeping gene
GAPDH confirms equivalent loading and intact RNA for all samples. (B)
CXCL12 activates AKT in HDMECs as determined by Western Blot. There
is CXCL12-dependent activation of AKT that remains greater than
control endothelium through 5 hours.
doi:10.1371/journal.pone.0005756.g005
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hydrophobicity of surfaces. Immediately afterwards, the top
channel was coated with a fibronectin solution (10 mgm l
21
PBS, 3 h, 37uC). Prior to cell seeding, the device was sterilized by
placing under UV light for ,30 min.
Endothelial cell culture and seeding
Human dermal microvascular cells (HDMECs, Lonza) passage
numbers 6–8 were cultured in EBM-2+5% FBS+SingleQuotH kit
(supplements such as VEGF, bFGF, etc) or EGM-2 MV (Lonza) as
described previously [43]. These cells are isolated from skin, a tissue
with low metastatic potential for breast cancer [10], and facilitate
low amounts of adhesion of cancer cells under non-stimulated
conditions [44]. A concentrated solution of HDMECs (,10
7 cells
ml
21 EGM-2 MV) was loaded through the funnel-shaped inlet
reservoir, allowed to attach along the entire length of the top
channel. Cells were re-fed 1–2 times per day by gravity flow from
the funnel-shaped inlet and through the top channel and grown to
confluence (24–48 h after seeding). We note that the presence of the
bottom channels (Figure 1E), which have relatively large volumes
compared to the top channel, helps guard against nutrient depletion
and evaporation prone to occur in PDMS-based microchannels
[45]. The concentrations for the HDMEC treatments in the
described experiments were 25 mmol Syto 64, 50 ng ml
21 TNF-a,
100 ng ml
21 CXCL12, and 80 ng ml
21 AMD3100. These con-
centrations are consistent throughout (except for CXCL12-Gaussia
described immediately below) and all of these treatments were in
EBM-2+SingleHQuots with no serum.
Quantifying cell-associated CXCL12-Gaussia luciferase
and Gaussia luciferase
293T cells stably transduced with lentiviral vectors for a fusion
protein of CXCL12 and Gaussia luciferase (CXCL12-GL) or
unfused Gaussia luciferase (GL) were plated in 6 cm dishes at
1610
5 cells per dish. One day after plating, cells were changed to
DMEM medium with 0.2% bovine serum albumin (BSA)
(Probumin, Celliance). Supernatants containing secreted
CXCL12-GL or GL were collected from cells 18 hours later,
and levels of CXCL12-GL were measured by ELISA (R&D
Systems). Supernatants from CXCL12-GL secreting cells con-
tained <40 ng ml
21 CXCL12, while this chemokine was
undetectable in supernatants from GL secreting cells. CXCL12-
GL has bioluminescence properties comparable to unfused GL
and CXCR4-dependent signaling to a comparable extent as
unfused secreted or synthetic CXCL12. Full characterization of
CXCL12-GL will be described in a separate manuscript.
HDMEC cultured on 24-well Transwell inserts (Corning) were
incubated for 5 hours with <40 ng ml
21 CXCL12-GL or a
comparable amount of GL based on luminescence either in the
top (apical) or bottom (basal) compartments of the Transwell
insert. Cells and Transwell inserts were washed twice with PBS
before adding 1 mgm l
21 coelenterazine (Fluka) in PBS and
measuring bioluminescence in intact cells on an IVIS 100 system
(Caliper). Images were obtained for 20–30 seconds using high
resolution acquisition. Bioluminescence was quantified by region
of interest analysis using Living Image Software [46] (Figure 2A).
CXCR7 and CXCR4 expression in MDA-MB-231 human
breast cancer cells
Human MDA-MB-231 breast cancer cells [47] (ATCC) were
cultured in DMEM+10% FBS+1% L-glutamine+0.5% penicillin/
streptomycin. Lentiviral vectors for CXCR4-GFP, CXCR7-GFP,
or GFP control were used to stably transduce MDA-MB-231 cells
to create the described 231-CXCR4, 231-CXCR7, or 231-control
cells respectively that have native green fluorescence for clear
detection. Chemokine receptor expression in the 231-CXCR4,
Figure 6. Endothelial-CXCR4 dependent adhesion of cancer
cells. (A) Adhesion selectivity of 231-control cancer cells towards
regions of the endothelium treated with different combinations of
CXCL12, TNF-a and the CXCR4 inhibitor AMD3100 for 5 hours under
0.50 dyn cm
22 flow conditions (*). The levels of adhesion onto the
differently treated regions were statistically different (**). AMD3100 in
the presence of CXCL12 decreased adhesion by 34% relative to the
CXCL12 only condition (*). AMD3100 in the presence of CXCL12 and
TNF-a decreased adhesion 42% relative to CXCL12+TNF-a (*). The
dotted line represents a ratio of 1 or no adhesion selectivity. (B) Same as
(A) except the experiments were performed under 2.50 dyn cm
22 flow
conditions. n=4–6 for each condition. (C) Adhesion of 231-control
cancer cells is not affected by pre-treatment with chemokine receptor
inhibitors. 231-control cells were pre-treated for 5 h with either an
inhibitor for CXCR4 (AMD3100) or an anti-CXCR7 antibody (11G8) and
compared to no pre-treatment. The level of adhesion was statistically
the same for all three conditions onto either CXCL12 treated (5 h) or
untreated endothelium (#,p .0.34). For all 231-control cell pre-
treatment conditions, the level of adhesion was greater onto CXCL12
treated versus untreated endothelium (*). n=5–6 for each condition.
doi:10.1371/journal.pone.0005756.g006
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cytometry (Figure 3A) as we have described previously, using
mouse monoclonal antibodies to CXCR4 (12G5-PE, R&D
Systems) or CXCR7 (11G8-APC, gift of R&D Systems) [48].
RT-PCR
Total RNA from HDMECs (Figure 5A) was prepared using
Trizol reagent (Invitrogen) according to the manufacturer’s
protocol. RNA was purified further over an RNA extraction
column (Qiagen), including on-column treatment with DNaseI.
RT-PCR was performed using a two-step kit (ThermoScript,
Invitrogen). Sequences of PCR primers were the following:
CXCR4: 59-ACGGACAAGTACAGGCTGCAC-39 and 59-
CCCAGAAGGGAAGCGTGA-39
CXCR7: 59-AAGAAGATGGTACGCCGTGTCGTCTC-39
and 59-CTGCTGTGCTTCTCCTGGTCACTGGA-39
GAPDH: 59-GAAGGTGAAGGTCGGAGT-39 and 59-GAA-
GATGGTGATGGGATTTC-39
Western Blot
HDMECs were incubated with 100 ng ml
21 CXCL12 for
10 minutes or 5 hours. Control cells were incubated with BSA
alone. 231 breast cancer cells were cultured overnight in DMEM
medium containing 0.5% serum. Breast cancer cells then were
treated with 100 ng ml
21 CXCL12 (R&D Systems) for 3 or
10 minutes, respectively (Figure 5B). Total cell lysates were
harvested and prepared for Western blotting as described
previously [49]. Primary antibodies to AKT phosphorylated at
serine 473 and total AKT (Cell Signaling Technology) were used
at 1:500 dilution, and a secondary antibody to rabbit conjugated
with horseradish peroxidase was used at 1:2000 dilution. Western
blots were developed with ECL reagent (Amersham).
Calculation of shear stress levels
The shear stress levels on the cells within the channels were
modeled with the following equation [50,51]:
t~
6|2:95mQ2{D
h2 ð1Þ
Where t is the shear stress level at the cell apex, m is the viscosity of
the fluid (water=0.01 dyn?sc m
22 at room temperature), Q2-D is
the flow rate per width in the system and h is the height of the
channel. This equation is valid for cases where the width is much
larger than the height. In our system, the height of the channels
was 60 mm and the width was 800 mm.
Flow-based intravascular adhesion experiments
Prior to each experiment, the EGM-2 MV culture in the funnel-
inlet of the microfluidic device was removed, washed with PBS,
and replaced with EBM-2+SingleHQuots. Subsequently, the top
channel was washed with EBM-2+SingleHQuots by gravity-driven
flow. Concurrently, the bottom channels were triple washed with
PBS and replaced with either EBM-2+SingleHQuots (untreated) or
EBM-2+SingleHQuots+cytokine or chemokine of interest. The
flow in the top channel was stopped and the device was left to be
treated for 5 h. Concurrently, culture flasks of the 231 breast
cancer cells were washed with PBS and serum starved in EBM-
2+0.5% FBS for 5 h as well. For experiments involving pre-
treatment of 231 cells with chemokine receptor inhibitor
(Figure 6C), either AMD3100 (80 ng ml
21) for neutralizing
CXCR4 or 11G8 antibody (10 mgm l
21) for neutralizing CXCR7
is added to the EBM-2+0.5% FBS starve media.
After serum starvation, the breast cancer cells were collected using
citric saline, a calcium ion chelator, instead of trypsin to ensure cell
surface proteins remain intact. The cancer cells were centrifuged and
washed twice and resuspended in EBM-2+0.5% FBS at a
concentration of 2610
6 cells ml
21. The cancer cell suspension was
loaded into the funnel-shaped inlet. Flow was controlled using a
programmable syringe pump (KD Scientific) that withdraws fluid
away from the funnel-shaped inlet at flow rates corresponding with
shear stress levels of 0.50 dyn cm
22 or 2.50 dyn cm
22.W en o t et h a t
in our system, the shear stress levels of 0.50 dyn cm
22 and
2.50 dyn cm
22 correspond with flow velocities of 0.2 mm s
21 and
1.0 mm s
21 respectively which are in line with the in vivo blood flow
velocity range of 0.1–1.5 mm s
21 reported in the microcirculation of
potential sites of breast cancer metastasis [52–54]. Also, integrins on
the surface of circulating cells are reported to optimally mediate
adhesion onto endothelium at shear stress levels below
0.50 dyn cm
22 with the avidity decreasing rapidly with higher shear
stress levels [18]. Thus, the absolute number of cells attached is much
lower at 2.50 dyn cm
22 compared to 0.50 dyn cm
22.
The microfluidic device was placed on the stage of an epi-
fluorescence, inverted microscope (Nikon, TE-300). The duration
of each experiment was 30 min followed by a controlled 1 min
wash of the top channel with PBS to remove loosely attached cells.
Images were recorded with a digital CCD camera (Hamamatsu).
To determine cell counts, fluorescent cells in an entire region were
counted blindly by a different person other than the experimen-
talist to negate observer bias using a semi-automatic counting
protocol with NIH ImageJ and treated as one data point.
Static adhesion experiments
The conditions for the static adhesion experiments were the
same as the flow-based experiments described above in terms of
cells, pre-treatment, and duration of experiments. The difference
was the static experiments were performed in tissue culture 96-well
plates (Corning) instead of microfluidic devices. Into each well,
<10,000 cancer cells in 100 ml were added and allowed to adhere
for 30 minutes. Following the adhesion experiments, each well was
triple washed with PBS to remove loosely attached cells. For static
adhesion in Transwells (Figure 2B), HDMECs were grown to
confluence in 24-well plate Transwells similar to the CXCL12-GL
binding assays (Figure 2A). The adhesion experiments were
performed in the same manner as the 96-well plate experiments
described above with CXCL12 (100 ng ml
21) introduced either
apical or basal to the endothelium for 5 hours. Also, the same
amount of cancer cells and volume (10,000 cells in 100 ml) were
allowed to adhere since the surface area of the Transwell insert is
the same as an individual well in a 96-well plate (0.32–0.33 cm
2).
In these experiments, 10 minutes instead of 30 minutes were
allowed for adhesion prior to triplicate PBS washing.
Statistical analysis
Sample populations were compared either pair wise using the
Mann-Whitney U test or in groups of more than two using the
Kruskal-Wallis test. p,0.05 was the threshold for statistical
significance. Data sets that were statistically significant with the
Mann-Whitney U test were indicated with a ‘*’ symbol. For data
evaluated with the Kruskal-Wallis test, results that were statistically
significant were indicated with a ‘**’ symbol; results that were not
statistically significant were indicated with a ‘#’ symbol.
Supporting Information
Figure S1 231-control cells preferentially adhere onto TNF-a
stimulated endothelial region at 0.50 and 2.50 dyn cm
22 flow
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or downstream compartment (white bars) with the other
compartments in the same device left untreated. Cancer cell
adhesion onto the TNF-a treated endothelial region was
significantly greater than the untreated region regardless of if
TNF-a was applied upstream or downstream (p,0.01). (A)
0.50 dyn cm
22. (B) 2.50 dyn cm
22.‘ +’ denotes TNF-a stimula-
tion. n=3 each for upstream or downstream treated conditions.
Data are expressed as the mean+s.e.m. (C) Boxplots representing
adhesion selectivity of 231-control cells towards TNF-a treated
endothelium at 0, 0.50, and 2.50 dyn cm
22 shear stress levels. The
adhesion selectivity was statistically different for the different flow
conditions (**, p,0.05) with the selectivity increasing with
increasing flow. n=6 for each condition.
Found at: doi:10.1371/journal.pone.0005756.s001 (0.26 MB TIF)
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